Rapid syndromic molecular testing in pneumonia: The current landscape and future potential

Area of Science:

• Infectious Diseases
• Microbiology
• Clinical Diagnostics

Background:

• Community-acquired pneumonia (CAP), hospital-acquired pneumonia (HAP), and ventilator-associated pneumonia (VAP) are major causes of mortality and healthcare costs globally.
• Timely and appropriate antimicrobial treatment is essential for managing these infections effectively.

Purpose of the Study:

• To review currently available rapid multiplexed molecular testing platforms for pneumonia diagnosis.
• To discuss the potential benefits and challenges of implementing rapid diagnostic testing in clinical practice.

Main Methods:

• Review of existing literature on rapid molecular diagnostic platforms for pneumonia.
• Analysis of the advantages and disadvantages of syndromic testing approaches.

Main Results:

• Novel rapid multiplexed molecular platforms offer the potential for syndromic diagnostic testing in pneumonia.
• These platforms can facilitate rapid, targeted antimicrobial therapy, potentially improving patient outcomes.

Conclusions:

• Rapid diagnostic testing for pneumonia holds promise for enhancing patient care and supporting antibiotic stewardship efforts.
• Careful consideration of the benefits and pitfalls is necessary for successful implementation.